October 2022 in “British Journal of Dermatology” In this retrospective study, the incidence of hyperkalaemia within the first year of spironolactone use was assessed among women over 65 with female-pattern hair loss, highlighting a potential safety concern.
9 citations
,
June 2020 in “Actas Dermo-Sifiliográficas” This source suggests that spironolactone, a potassium-sparing diuretic, is underutilized in dermatology despite evidence showing its potential benefits for female acne, hidradenitis suppurativa, and female androgenetic alopecia, noting its long-term safety and reduced need for additional testing in young women.
This abstract reviews the use of spironolactone as a treatment for hormonal acne, female pattern hair loss, and hirsutism due to its antiandrogenic properties and favorable side effect profile, highlighting its value in dermatological therapies.
February 2024 in “Practical Diabetes” This study showed that spironolactone effectively reduces morbidity and mortality in moderate to severe heart failure with reduced ejection fraction, but its benefits in heart failure with preserved ejection fraction are less clear.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.